Sarepta Therapeutics stock experienced severe downward corrections and steep price crashes following catastrophic safety events and clinical holds associated with patient fatalities linked to its high-profile gene therapy treatments. These safety concerns triggered intense regulatory scrutiny, investigations, and investor fears regarding potential commercial suspensions or severe label restrictions, casting shadows over its broader neuromuscular disease product pipelines.